MT 303

Drug Profile

MT 303

Alternative Names: Glyceollin microbiome modulator - MicroBiome Therapeutics; MT-303

Latest Information Update: 05 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MicroBiome Therapeutics
  • Class Benzofurans; Isoflavones; Small molecules
  • Mechanism of Action Fatty acid inhibitors; Lipid inhibitors; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 01 Mar 2015 Preclinical trials in Obesity in USA (unspecified route) before March 2015
  • 09 Feb 2015 MicroBiome Therapeutics receives patent allowance for glyceollin in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top